<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Cancer</journal-id><journal-title>Molecular Cancer</journal-title><issn pub-type="epub">1476-4598</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1476-4598-4-16</article-id><article-id pub-id-type="pmid">15876350</article-id><article-id pub-id-type="doi">10.1186/1476-4598-4-16</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Amplification and overexpression of the <italic>ID4 </italic>gene at 6p22.3 in bladder cancer</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Wu</surname><given-names>Qiong</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>wu_qiong@yahoo.com</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Hoffmann</surname><given-names>Mich&#x000e8;le J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>michele.hoffmann@uni-duesseldorf.de</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Hartmann</surname><given-names>Florian H</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>florianh.hartmann@uni-duesseldorf.de</email></contrib><contrib id="A4" corresp="yes" contrib-type="author"><name><surname>Schulz</surname><given-names>Wolfgang A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>wolfgang.schulz@uni-duesseldorf.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Dept. of Urology, Heinrich Heine University, D&#x000fc;sseldorf, Germany</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>5</day><month>5</month><year>2005</year></pub-date><volume>4</volume><fpage>16</fpage><lpage>16</lpage><ext-link ext-link-type="uri" xlink:href="http://www.molecular-cancer.com/content/4/1/16"/><history><date date-type="received"><day>9</day><month>2</month><year>2005</year></date><date date-type="accepted"><day>5</day><month>5</month><year>2005</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2005 Wu et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>Wu et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Wu Qiong wu_qiong@yahoo.com </dc:author><dc:title> Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer </dc:title><dc:date>2005</dc:date><dcterms:bibliographicCitation>Molecular Cancer 4(1): 16-. (2005)</dcterms:bibliographicCitation><dc:identifier type="sici">1476-4598(2005)4:1&#x0003c;16&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1476-4598</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Amplifications at 6p22.3 are prevalent in advanced stage bladder cancer (TCC). Previous studies have identified <italic>SOX4</italic>, <italic>CDKAL</italic>, and <italic>E2F3 </italic>as targets of this amplification and therefore potential oncogenes, but the more telomeric <italic>DEK </italic>gene too has been reported as overexpressed and amplified. We have therefore investigated whether the intermediate region harboring the oncogene candidate <italic>ID4 </italic>is also part of the amplicon.</p></sec><sec><title>Results</title><p>Expression of <italic>E2F3</italic>, <italic>DEK</italic>, and <italic>ID4 </italic>was investigated by real-time RT-PCR in 28 TCC compared to 6 normal bladder tissues and in 15 TCC cell lines compared to cultured normal urothelial cells. Expression of <italic>E2F3 </italic>as well as <italic>DEK </italic>increased on average in tumor vs. normal tissues (3-fold and 2.5-fold, resp.), but only the increase for <italic>E2F3 </italic>was statistically significant (p = 0.039). ID4 overexpression was observed in selected specimens. Each of the three genes was overexpressed in several cell lines, up to 150-fold (<italic>ID4</italic>), 30-fold (<italic>E2F3</italic>), and 9-fold (<italic>DEK</italic>), but these increases were not correlated to each other. Instead, moderate (<italic>DEK</italic>) to excellent (<italic>ID4</italic>) correlations were observed with copy number increases of microsatellites near each gene. Microsatellite copy number increases were highly heterogeneous across the investigated several Mb region revealing at least three subregions of amplification.</p></sec><sec><title>Conclusion</title><p>Extending previous reports, our data indicate that the 6p22.3 amplicon in TCC is highly heterogeneous and targets several genes in a variable fashion. Among these, expression of <italic>E2F3 </italic>and <italic>DEK </italic>appear to be generally increased in TCC, with additional increases caused by amplifications. In contrast, over-expression of <italic>ID4</italic>, which is normally predominantly expressed in testes and brain, appears to depend more strictly on gene amplification. Accordingly, the effect of amplifications at 6p22.3 in bladder cancer is expected to be non-uniform, thereby contributing to the highly variable biological and clinical behavior of advanced stage tumors. <italic>ID4 </italic>is a potential oncogene in a small subset of bladder cancers.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Urothelial carcinoma, which is commonly called bladder cancer, occurs in two forms, a more prevalent papillary subtype and a rarer, but much more invasive subtype [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Invasive bladder cancers usually develop from highly dysplastic carcinoma in situ, but some papillary tumors also progress to an invasive form. While papillary cancers often contain a limited number of chromosomal alterations, invasive cancers are characterized by a high degree of chromosomal instability [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Even T1 stage cancers, which have only invaded the lamina propria underlying the urothelium, often exhibit multiple chromosomal changes. Cancers at more advanced stages accumulate further chromosomal alterations. In particular, they harbor amplifications, e.g. of regions from chromosomes 5p, 6p, 8q, 11q, and 20q [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. It is generally assumed that chromosomal segments consistently amplified in a cancer contain oncogenes [<xref ref-type="bibr" rid="B8">8</xref>]. Accordingly, genes amplified in advanced bladder cancers would be expected to contribute to the progression of this cancer.</p><p>One of the most consistently amplified region in advanced bladder cancers is located at 6p22.3 [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. This amplification is detected in up to 25% of advanced stage bladder cancers and is present in many bladder cancer cell lines. The cell lines harboring this amplification provide a convenient experimental access to map the amplified region precisely and identify potential urothelial carcinoma oncogenes. Mapping of the 6p22.3 amplicon has been performed by several groups who have identified different genes as potential targets of the amplification (Figure <xref ref-type="fig" rid="F1">1</xref>). In a first study [<xref ref-type="bibr" rid="B5">5</xref>], <italic>SOX4 </italic>was identified as a frequent, but not entirely consistent amplification target. Further studies revealed that many amplifications also included <italic>E2F3 </italic>and the encoded protein was over-expressed, particularly in high stage and high grade urothelial cancers [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. A high resolution analysis by microarray-based comparative genomic hybridization identified <italic>CDKAL1 </italic>located between <italic>SOX4 </italic>and <italic>E2F3 </italic>as the most commonly amplified gene [<xref ref-type="bibr" rid="B7">7</xref>]. Another study indicated that <italic>DEK </italic>located further telomerically (Figure <xref ref-type="fig" rid="F1">1</xref>) may be amplified in a substantial proportion of bladder cancer tissues [<xref ref-type="bibr" rid="B10">10</xref>]. <italic>DEK </italic>was also found to be over-expressed in a cDNA microarray study, albeit predominantly in early stage tumors [<xref ref-type="bibr" rid="B12">12</xref>].</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>The chromosome 6p22.3 region</bold>. Verified genes are drawn to size as grey boxes and the location of microsatellites used (the prefix D6S is omitted) is indicated.</p></caption><graphic xlink:href="1476-4598-4-16-1"/></fig><p>This somewhat confusing state may owe partly to the fact that many studies were performed prior to the publication of the finished sequence of chromosome 6 in October 2003 [<xref ref-type="bibr" rid="B14">14</xref>] and partly to the use of different techniques. Alternatively, the differences between the studies could also mean that the region of amplification is not uniform and that multiple genes might be targets.</p><p>Most previous studies have focussed on a more centromeric region within 6p22.3 containing <italic>SOX4</italic>, <italic>CDKAL1</italic>, and <italic>E2F3 </italic>(Figure <xref ref-type="fig" rid="F1">1</xref>). <italic>DEK </italic>is located about 2 Mb more telomeric of these genes. The interval framed by <italic>E2F3 </italic>and <italic>DEK </italic>contains another plausible oncogene candidate, i.e. <italic>ID4</italic>. The ID proteins ('inhibitor of differentiation') are named for their ability to bind and inhibit cell-type specific helix-loop-helix transcriptional activators inducing cell differentiation. Accordingly, they tend to stimulate cell proliferation, and have been implicated in various cancers [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. Compared to ID1 and ID2, ID4 is a less well characterized member of the family. It is expressed in a tissue-specific manner, with the highest levels in testes and brain [<xref ref-type="bibr" rid="B19">19</xref>]. In the present study, we have therefore investigated to which extent <italic>ID4 </italic>gene copy numbers and expression are affected by 6p22 amplifications in bladder cancer, in comparison to <italic>E2F3 </italic>and <italic>DEK</italic>.</p></sec><sec><title>Results</title><sec><title>Expression of 6p22 genes in bladder cancer cell lines</title><p>First, expression of ID4 mRNA in comparison to E2F3 and DEK mRNAs was investigated by real-time PCR in 16 TCC cell lines (Figure <xref ref-type="fig" rid="F2">2</xref>). Normal urothelial cells (UP) proliferating in culture and testicular tissue samples served as controls. Expression at least twice as strong as in normal urothelial cells was considered as over-expression. According to this criterion, twelve cell lines over-expressed <italic>ID4</italic>, with a maximum &#x0003e;150fold increase in HT1376. In 6 cell lines, <italic>E2F3 </italic>was over-expressed. The <italic>E2F3 </italic>over-expressing cell lines included HT1376 and 5637 in line with previous reports [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. 5637 displayed a &#x0003e;30fold increased level of E2F3 mRNA. Six cell lines over-expressed <italic>DEK</italic>, although the relative increases were in general more moderate, with a maximum 9fold increase in RT112. Inspecting Figure <xref ref-type="fig" rid="F2">2</xref> may suggest that cell lines over-expressing one gene also tended to over-express one or both others. However, this tendency was not reflected in a statistically significant correlation. Specifically, expression did not significantly correlate for any pair of genes, the best correlation coefficient reaching 0.39 between <italic>ID4 </italic>and <italic>DEK</italic>. The divergence is strikingly illustrated by the cell lines HT1376 and 5637, which presented increased expression levels for all three genes, but with either <italic>ID4 </italic>or <italic>E2F3 </italic>displaying particularly pronounced increases (Figure <xref ref-type="fig" rid="F2">2</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Expression of 6p22 genes in bladder cancer cell lines</bold>. Levels of mRNAs for ID4 (grey bars), E2F3 (black bars), and DEK (white bars) were determined by real-time RT-PCR relative to &#x003b2;-actin mRNA. As controls, shown to the left and right of the cancer cell lines, two independent primary cultures of normal urothelial cells (UP93 and UP94) and two different normal testicular tissues were used. All values were determined by at least triplicate measurements, with further repeats, if deviations exceeded 20% of the mean. Arbitrary units are given; values for E2F3 and DEK were divided by 10.</p></caption><graphic xlink:href="1476-4598-4-16-2"/></fig></sec><sec><title>Gene amplification analysis</title><p>To determine whether the increases in mRNA expression were due to gene amplification, copy numbers were investigated for eight microsatellite loci located in 6p22.3. Five were located around <italic>ID4</italic>, from D6S422 close to <italic>E2F3 </italic>to DS1946, and three were located around <italic>DEK</italic>, including the intragenic marker D6S2051 (Figure <xref ref-type="fig" rid="F1">1</xref>). The results (Figure <xref ref-type="fig" rid="F3">3</xref>) demonstrate a considerable variation in the microsatellite copy numbers across the region, even within the same cell line. For instance, in HT1376 the copy numbers of the eight microsatellites ranged from approximately 0.5 to 13 normal genome equivalents, which would correspond to 1 &#x02013; 26 copies in a diploid cell. As all bladder cancer cell lines are aneuploid, typically hypo- or hypertriploid with a modal distribution, between 2 &#x02013; 40 copies would be present in a single cell. In HT1376 specifically, two different segments of amplification are discernible, one telomeric to <italic>DEK </italic>and one around <italic>ID4</italic>. In fact, amplification of the region including <italic>E2F3 </italic>and of <italic>SOX4 </italic>has been shown previously in this line [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. Thus, there are at least three distinct regions of amplification in this cell line. In contrast, no amplification of microsatellites telomeric of D6S422 was evident in 5637, which contains increased copy numbers of <italic>E2F3 </italic>and <italic>SOX4 </italic>[<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. A more homogeneous increase of all more telomeric markers including those close to <italic>ID4 </italic>and <italic>DEK </italic>was seen in J82. RT112 contained a selective amplification of the D6S2051 marker located in the <italic>DEK </italic>gene in accord with the maximum expression of this gene in this cell line. None of the microsatellites showed increased copy numbers in T24 or SD, although <italic>E2F3 </italic>as well as <italic>DEK</italic>, but not <italic>ID4 </italic>were overexpressed in T24.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Copy numbers of 6p22 microsatellites in bladder cancer cell lines</bold>. Microsatellite copy numbers (see Fig. 1 for their location) were determined as described in the methods section in the cell lines (A-F) HT1376, 5637, J82, RT112, SD, and T24. Normal genome equivalents determined from leukocyte DNA were set as 1.</p></caption><graphic xlink:href="1476-4598-4-16-3"/></fig><p>Expression of <italic>ID4 </italic>correlated excellently with the copy numbers of each of the microsatellites around the gene, yielding coefficients between 0.89 and 0.95 (Figure <xref ref-type="fig" rid="F4">4A</xref>). A closer inspection shows however that this strong correlation is primarily caused by the cell lines with clear-cut amplifications of the region, i.e. J82 and HT1376 while at lower copy numbers the relationship is essentially random. <italic>DEK </italic>expression correlated moderately well with the copy number of the intragenic D6S2051 marker (Figure <xref ref-type="fig" rid="F4">4B</xref>). <italic>E2F3 </italic>expression showed the best correlation with the microsatellite marker D6S422 located most closely to the gene (Figure <xref ref-type="fig" rid="F4">4C</xref>). However, this apparent correlation was mostly due to the strongly increased copy number of D6S422 in the 5637 cell line; if this data point is removed, the relationship is essentially random.</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Relationship of 6p22 gene expression changes to copy number changes of adjacent microsatellites in bladder cancer cell lines</bold>. A: ID4 mRNA vs. D6S1128E (r = 0.95), B: DEK mRNA vs. D6S2051 (r = 0.57), C: E2F3 mRNA vs. D6S422 (r = 0.79),</p></caption><graphic xlink:href="1476-4598-4-16-4"/></fig></sec><sec><title>6p22 gene expression in bladder cancer tissues</title><p>To determine whether the results from the cell lines can be extended to bladder cancer tissues, the expression of the three genes was determined in 28 tumor tissue samples and 6 morphological normal samples from cystectomy specimens by real-time RT-PCR (Figure <xref ref-type="fig" rid="F5">5</xref>, Table <xref ref-type="table" rid="T1">1</xref>). In accord with previous reports, expression of E2F3 mRNA and DEK mRNA were often increased in tumor compared to normal tissues. Median E2F3 mRNA expression was 2.24 arbitrary units in cancers compared to 0.72 in normal tissues, i.e. about threefold higher. This difference was statistically significant (p = 0.039). Median DEK mRNA expression was 1.26 compared to 0.52, i.e. 2.5fold higher, but the difference did not reach statistical significance. In contrast, ID4 expression essentially did not differ between normal and cancer tissues. Instead, individual cancer specimens showed strongly increased expression beyond the range of normal tissues.</p><fig position="float" id="F5"><label>Figure 5</label><caption><p><bold>Expression of genes at 6p22.3 in bladder cancer tissues</bold>. Box plot representation of ID4 (left), E2F3 (center), and DEK (right) mRNA expression relative to &#x003b2;-actin mRNA as determined by real-time RT-PCR in 28 bladder cancer tissues (see Table 1) and 6 morphologically normal bladder tissues. Note the different scales in the three figure parts.</p></caption><graphic xlink:href="1476-4598-4-16-5"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Tumor tissues investigated</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="2"><bold>Patient</bold></td><td align="center" colspan="4"><bold>Tumor</bold></td><td align="center" colspan="3"><bold>mRNA expression (AU)</bold></td></tr></thead><tbody><tr><td align="center"><bold>No</bold></td><td align="center"><bold>Sex</bold></td><td align="center"><bold>Age</bold></td><td align="center"><bold>Stage</bold></td><td align="center"><bold>Lymph node status</bold></td><td align="center"><bold>Metastasis status</bold></td><td align="center"><bold>Grade</bold></td><td align="center"><bold>E2F3</bold></td><td align="center"><bold>ID4</bold></td><td align="center"><bold>DEK</bold></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="center">3</td><td align="center">m</td><td align="center">75</td><td align="center">pT3b</td><td align="center">N0</td><td align="center">M0</td><td align="center">G2</td><td align="right">5.59</td><td align="right">0.48</td><td align="right">4.88</td></tr><tr><td align="center">6</td><td align="center">m</td><td align="center">76</td><td align="center">pT3b</td><td align="center">pN2</td><td align="center">M0</td><td align="center">G3</td><td align="right">10.37</td><td align="right">0.36</td><td align="right">1.37</td></tr><tr><td align="center">12</td><td align="center">m</td><td align="center">70</td><td align="center">pT3a</td><td align="center">N0</td><td align="center">M0</td><td align="center">G3</td><td align="right">1.73</td><td align="right">0.04</td><td align="right">1.99</td></tr><tr><td align="center">28</td><td align="center">m</td><td align="center">72</td><td align="center">pT3b</td><td align="center">N0</td><td align="center">M0</td><td align="center">G3</td><td align="right">3.73</td><td align="right">0.24</td><td align="right">2.27</td></tr><tr><td align="center">41</td><td align="center">f</td><td align="center">54</td><td align="center">pTa</td><td align="center">Nx</td><td align="center">Mx</td><td align="center">G2</td><td align="right">11.69</td><td align="right">0.49</td><td align="right">3.29</td></tr><tr><td align="center">47</td><td align="center">m</td><td align="center">76</td><td align="center">pT3b</td><td align="center">N0</td><td align="center">M0</td><td align="center">G3</td><td align="right">3.75</td><td align="right">0.19</td><td align="right">1.84</td></tr><tr><td align="center">52</td><td align="center">f</td><td align="center">87</td><td align="center">pT3b</td><td align="center">N0</td><td align="center">M0</td><td align="center">G3</td><td align="right">2.86</td><td align="right">0.25</td><td align="right">1.43</td></tr><tr><td align="center">55</td><td align="center">m</td><td align="center">83</td><td align="center">pT4a</td><td align="center">N1</td><td align="center">M0</td><td align="center">G3</td><td align="right">1.25</td><td align="right">0.18</td><td align="right">0.52</td></tr><tr><td align="center">61</td><td align="center">m</td><td align="center">75</td><td align="center">pT3b</td><td align="center">N0</td><td align="center">M0</td><td align="center">G3</td><td align="right">1.98</td><td align="right">0.12</td><td align="right">1.48</td></tr><tr><td align="center">62</td><td align="center">f</td><td align="center">78</td><td align="center">pT3b</td><td align="center">N0</td><td align="center">M0</td><td align="center">G2</td><td align="right">1.60</td><td align="right">0.54</td><td align="right">0.72</td></tr><tr><td align="center">64</td><td align="center">m</td><td align="center">74</td><td align="center">pT3b</td><td align="center">N2</td><td align="center">M0</td><td align="center">G3</td><td align="right">3.34</td><td align="right">0.11</td><td align="right">1.26</td></tr><tr><td align="center">67</td><td align="center">f</td><td align="center">94</td><td align="center">&#x0003e;pT2</td><td align="center">Nx</td><td align="center">Mx</td><td align="center">G3</td><td align="right">4.38</td><td align="right">0.33</td><td align="right">1.50</td></tr><tr><td align="center">69</td><td align="center">m</td><td align="center">77</td><td align="center">pT3b</td><td align="center">N0</td><td align="center">M0</td><td align="center">G3</td><td align="right">2.17</td><td align="right">0.14</td><td align="right">1.19</td></tr><tr><td align="center">104</td><td align="center">m</td><td align="center">61</td><td align="center">pT1</td><td align="center">N0</td><td align="center">M0</td><td align="center">G2</td><td align="right">1.49</td><td align="right">0.24</td><td align="right">0.72</td></tr><tr><td align="center">105</td><td align="center">m</td><td align="center">83</td><td align="center">pTa</td><td align="center">Nx</td><td align="center">M0</td><td align="center">G2</td><td align="right">3.80</td><td align="right">0.27</td><td align="right">1.88</td></tr><tr><td align="center">109</td><td align="center">m</td><td align="center">68</td><td align="center">pT4a</td><td align="center">N0</td><td align="center">M0</td><td align="center">G3</td><td align="right">2.14</td><td align="right">0.23</td><td align="right">0.30</td></tr><tr><td align="center">111</td><td align="center">m</td><td align="center">81</td><td align="center">pT3b</td><td align="center">N0</td><td align="center">M0</td><td align="center">G2-3</td><td align="right">2.24</td><td align="right">0.52</td><td align="right">0.61</td></tr><tr><td align="center">115</td><td align="center">m</td><td align="center">74</td><td align="center">pT3a</td><td align="center">N2</td><td align="center">M0</td><td align="center">G3</td><td align="right">1.74</td><td align="right">0.12</td><td align="right">0.84</td></tr><tr><td align="center">120</td><td align="center">m</td><td align="center">66</td><td align="center">pT2</td><td align="center">N0</td><td align="center">Mx</td><td align="center">G2</td><td align="right">3.12</td><td align="right">0.15</td><td align="right">0.66</td></tr><tr><td align="center">150</td><td align="center">f</td><td align="center">78</td><td align="center">pT3a</td><td align="center">N2</td><td align="center">M0</td><td align="center">G3</td><td align="right">0.54</td><td align="right">0.20</td><td align="right">0.86</td></tr><tr><td align="center">168</td><td align="center">m</td><td align="center">64</td><td align="center">pT3a</td><td align="center">N2</td><td align="center">M0</td><td align="center">G3</td><td align="right">1.68</td><td align="right">0.12</td><td align="right">1.42</td></tr><tr><td align="center">170</td><td align="center">f</td><td align="center">63</td><td align="center">pT2</td><td align="center">N0</td><td align="center">M0</td><td align="center">G2</td><td align="right">0.58</td><td align="right">0.08</td><td align="right">0.27</td></tr><tr><td align="center">172</td><td align="center">m</td><td align="center">72</td><td align="center">pT3a</td><td align="center">N0</td><td align="center">M0</td><td align="center">G3</td><td align="right">1.73</td><td align="right">0.13</td><td align="right">0.85</td></tr><tr><td align="center">205</td><td align="center">f</td><td align="center">65</td><td align="center">pT2</td><td align="center">N0</td><td align="center">M0</td><td align="center">G2</td><td align="right">0.36</td><td align="right">0.10</td><td align="right">0.17</td></tr><tr><td align="center">212</td><td align="center">m</td><td align="center">73</td><td align="center">pT2a</td><td align="center">N1</td><td align="center">M0</td><td align="center">G2</td><td align="right">0.62</td><td align="right">0.16</td><td align="right">0.79</td></tr><tr><td align="center">224</td><td align="center">m</td><td align="center">65</td><td align="center">pT2a</td><td align="center">N0</td><td align="center">M0</td><td align="center">G2</td><td align="right">4.29</td><td align="right">3.39</td><td align="right">1.87</td></tr><tr><td align="center">231</td><td align="center">m</td><td align="center">95</td><td align="center">&#x0003e;pT2</td><td align="center">Nx</td><td align="center">M0</td><td align="center">G2</td><td align="right">13.04</td><td align="right">1.11</td><td align="right">1.59</td></tr><tr><td align="center">246</td><td align="center">m</td><td align="center">67</td><td align="center">pT4a</td><td align="center">N2</td><td align="center">M0</td><td align="center">G3</td><td align="right">3.07</td><td align="right">0.27</td><td align="right">1.29</td></tr></tbody></table></table-wrap></sec></sec><sec><title>Discussion</title><p>Taken together with previous analyses of 6p22.3 amplifications in bladder cancer, the present study has implications concerning the structure of 6p22.3 amplicons, the effect of the amplification on gene expression, and more generally, concepts of the significance of gene amplification in human cancers. Specifically, the findings raise interesting aspects with regard to <italic>ID4</italic>.</p><p>Our findings indicate that 6p22.3 amplifications in bladder cancer are even more heterogeneous than hitherto assumed. Previous studies have identified the centromeric region around <italic>CDKAL1 </italic>as part of an amplicon that often, but not consistently included <italic>SOX4 </italic>and <italic>E2F3 </italic>[<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>]. The telomeric region around <italic>DEK </italic>had not been investigated as well yet [<xref ref-type="bibr" rid="B10">10</xref>]. Our study confirms that this region is also subject to copy number gains and amplifications. Specifically, our findings are in good accord with ref. [<xref ref-type="bibr" rid="B10">10</xref>] describing frequent copy numbers gains of microsatellites around <italic>DEK</italic>, but at highly variable frequencies. The three markers investigated in that study were located within 0.5 Mb and were amplified contiguously in 24% of the specimens, whereas each of these three markers individually was amplified in 45%, 56%, and 64% of the cases. Thus, upon closer analysis, this region of amplification appears also heterogeneous in itself. The intermediate region harboring <italic>ID4 </italic>had been more or less disregarded in previous studies, but our data indicate that it is clearly gained or even amplified in a certain number of cases, sometimes concomitantly with, and sometimes independent of the other two regions. In summary, therefore, one might discern three main segments of amplification, which split up into further subregions in individual cancers. The 6p22.3 amplicon therefore seems to belong to a class which is characterized by pronounced heterogeneity and great structural complexity (see below).</p><p>Previous studies have variously identified <italic>SOX4</italic>, <italic>E2F3</italic>, <italic>CDKAL1</italic>, and <italic>DEK </italic>as potential targets of the 6p22.3 amplification; the present study adds <italic>ID4 </italic>to this list. In this regard, it is interesting to compare the cell line data, where <italic>ID4 </italic>emerged as the most frequently over-expressed gene with the tissue data which showed generalized increases in expression of <italic>E2F3 </italic>and of <italic>DEK </italic>(Figure <xref ref-type="fig" rid="F1">1</xref> vs. Figure <xref ref-type="fig" rid="F5">5</xref>). This apparent discrepancy can be relatively simply resolved by two plausible assumptions. Normal bladder tissue is largely quiescent, albeit proliferation increases strongly in response to tissue damage [<xref ref-type="bibr" rid="B20">20</xref>]. Thus, urothelial cancers are distinguished from normal tissue not only by expression of cancer-specific genes, but also by generalized over-expression of genes associated with cell proliferation. The generally increased expression of <italic>E2F3 </italic>and <italic>DEK </italic>in the cancer tissues may reflect the latter effect, with further increases in individual cases due to deregulation and copy number gains of these genes. In contrast, early passage cultured urothelial cells proliferate as rapidly as cancer cell lines [<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B23">23</xref>]. Therefore, the increases in <italic>E2F3 </italic>and <italic>DEK </italic>in cultured cancer vs. normal cells may turn out as comparatively moderate. In contrast, <italic>ID4 </italic>expression has probably to be considered as ectopic in bladder cancer, since it is normally restricted to other tissues including testes and brain [<xref ref-type="bibr" rid="B19">19</xref>]. Thus, overexpression may more strictly depend on amplification of the gene, particularly in tumor tissues.</p><p>It is commonly assumed that regions in the genome that are amplified in cancers harbor proto-oncogenes that are activated by overexpression as a consequence of increased gene dosage. Indeed, several bona fide oncogenes have been found in amplified regions and some have even been identified by cloning from amplicons. In such cases, amplicons consistently contain one particular gene, alone or together with a limited number of others, e.g. <italic>ERBB2 </italic>only or together with <italic>TOP2A</italic>. Interestingly, the structure of such amplicons can be quite simple [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>]. The mechanism underlying such amplifications is not understood in detail, but appears to involve the re-replication of a single chromosome fragment, most likely via a circular double-minute intermediate [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>Clearly, the 6p22 amplicon in bladder cancer belongs to a different class of amplicons which are characterized by great heterogeneity and instability. Such amplicons often contain different segments and accordingly different genes from one region and even sequences from different chromosomes [<xref ref-type="bibr" rid="B27">27</xref>-<xref ref-type="bibr" rid="B30">30</xref>]. The mechanism causing these amplifications is considered to be most likely breakage-fusion-bridge cycles initiated e.g. by hypoxia [<xref ref-type="bibr" rid="B31">31</xref>] or breakage at fragile sites [<xref ref-type="bibr" rid="B32">32</xref>].</p><p>Considering this background, the question which is the oncogene targeted by 6p22 amplifications in bladder cancer and the specific issue of the role of <italic>ID4 </italic>have to be approached with due caution, since in each individual case the amplicon may be influenced by random factors such as the location of an initiating double-strand break and structural factors such as preferred sites of breakage of dicentric chromosomes arising during breakage-fusion-bridge cycles. Nevertheless, the relatively high prevalence of 6p22 amplifications in bladder cancer and the relative specificity of this amplification for this cancer type argue for a functional selection as well.</p><p>For several 6p22 genes subject to amplification, it is plausible to assume that their overexpression may confer a more aggressive phenotype to bladder cancer cells. SOX factors determine cell fate and cell differentiation [<xref ref-type="bibr" rid="B33">33</xref>], so <italic>SOX4 </italic>overexpression might lead to further dedifferentiation. E2F transcription factors activate the transcription of genes required for DNA synthesis and E2F3 appears to repress some promoters that are activated by E2F1, including the ARF promoter in <italic>CDKN2A </italic>[<xref ref-type="bibr" rid="B34">34</xref>]. DEK is part of a oncogenic fusion protein resulting from t(6;9)(p23;q34) translocations in acute myeloid leukemia [<xref ref-type="bibr" rid="B35">35</xref>] and is implicated in regulation of chromatin structure, which is evidently aberrant in invasive bladder cancers. However, specific functional studies on the role of these proteins in urothelial cells are lacking. The function of CDKAL1 is entirely unknown.</p><p>ID4 belongs to a protein family whose members have been shown to interfere with cell differentiation by blocking the effects of HLH transcription factors and pocket proteins, including RB1. Several members have been reported to be over-expressed in human cancers [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. <italic>ID4 </italic>in particular has been shown to be overexpressed in rat mammary carcinomas. Accordingly, overexpression of ID4 blocked the differentiation of HC11 mammary epithelial cells and stimulated their proliferation [<xref ref-type="bibr" rid="B36">36</xref>]. It is also the target of a specific chromosomal translocation in some cases of B-cell acute lymphoblastic leukemia [<xref ref-type="bibr" rid="B37">37</xref>]. Conversely, ID4 expression has been reported to be down-regulated by promoter hypermethylation in colon carcinomas [<xref ref-type="bibr" rid="B38">38</xref>]. Evidently, as for the other oncogene candidates on 6p22, more detailed studies are required on the biochemical and functional properties of ID4 in normal and cancerous urothelial tissue.</p></sec><sec><title>Conclusion</title><p>In conclusion, our study indicates that the 6p22.3 amplification prevalent in advanced bladder cancers is highly heterogeneous and contributes to the altered expression of several genes, including <italic>ID4</italic>, in a highly variable manner. Thus, this genetic change may contribute to the highly variable biological and clinical behaviour of invasive bladder cancers.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Tissues</title><p>Cancerous and normal bladder tissues were used from a previous study [<xref ref-type="bibr" rid="B39">39</xref>]. Normal tissues were identified by gross morphology, with microscopic verification in case of extended tumors. Important clinical parameters of the cancer tissues are summarized in Table <xref ref-type="table" rid="T1">1</xref>. RNA from testicular normal and cancer tissues used as a control for ID4 expression was also prepared in the course of a former study [<xref ref-type="bibr" rid="B40">40</xref>].</p></sec><sec><title>Cell lines and primary cultures</title><p>The bladder cancer cell lines 253J, 639v, 5637, BFTC905, BFTC909, EJ, HT1376, J82, MGHU4, RT112, SD, SW1710, T24, UMUC3, VMCub1, and VMCub2 and primary urothelial cells were cultured as described previously [<xref ref-type="bibr" rid="B23">23</xref>].</p></sec><sec><title>DNA and RNA extraction</title><p>High-quality DNA and RNA were extracted by standard methods using commercial kits from Qiagen (Hilden, Germany) and Peqlab (Erlangen, Germany).</p></sec><sec><title>RT-PCR</title><p>Following photometric quantification, 2 &#x003bc;g mRNA were transcribed into first strand cDNA using SuperscriptII (Invitrogen, Karlsruhe, Germany) according to the manufacturer's protocol with oligo-dT primers. Real-time RT-PCR was carried out using a LightCycler instrument (Roche Diagnostics, Mannheim, Germany) and the primers indicated in Table <xref ref-type="table" rid="T2">2</xref>. The amplification mixture consisted of 1x reaction mix (LightCycler-FastStart DNA Master PLUS SYBR Green I; Roche Diagnostics), 10 pmoles (<italic>DEK</italic>, <italic>E2F3</italic>, <italic>ID4</italic>) or 5 pmoles (&#x003b2;-actin) of each primer and 20 ng cDNA in a final volume of 10 &#x003bc;l. The reaction was monitored between the annealing and elongation steps at 640 nm. After the final cycle, melting-point analysis of the samples was performed over the range of 69&#x000b0;C &#x02013; 99&#x000b0;C. Turning-point values for the specific genes were related to those for &#x003b2;-actin.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>RT-PCR primers and conditions</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Designation</td><td align="center">Sequence</td><td align="center">T<sub>m</sub>(&#x000b0;C)</td><td align="center">Product size (bp)</td></tr></thead><tbody><tr><td align="left">GAPDH 350s</td><td align="left">TCCCATCACCATCTTCCA</td><td align="center">62.3</td><td align="center">379</td></tr><tr><td align="left">GAPDH 350as</td><td align="left">CATCACGCCACAGTTTCC</td><td align="center">61.9</td><td></td></tr><tr><td align="left">Aktin661S</td><td align="left">TGACGGGGTCAC</td><td align="center">72.2</td><td align="center">661</td></tr><tr><td align="left">Aktin661AS</td><td align="left">CTAGAAGCATTT</td><td align="center">70.9</td><td></td></tr><tr><td align="left">ID4 fw</td><td align="left">CCGCCCAACAAGAAAGTCAG</td><td align="center">59.4</td><td align="center">188</td></tr><tr><td align="left">ID4 rv</td><td align="left">GGTGTTGAGCGCAGTGAG</td><td align="center">58.2</td><td></td></tr><tr><td align="left">E2F3 fw</td><td align="left">ACGTCTCTTGGTCTGCTCAC</td><td align="center">59.4</td><td align="center">155</td></tr><tr><td align="left">E2F3 rv</td><td align="left">TCTTAATGAGGTGGATGCCT</td><td align="center">55.3</td><td></td></tr><tr><td align="left">DEK fw</td><td align="left">GTGGGTCAGTTCAGTGGC</td><td align="center">58.2</td><td align="center">291</td></tr><tr><td align="left">DEK rv</td><td align="left">AGGACATTTGGTTCGCTTAG</td><td align="center">55.3</td><td></td></tr></tbody></table></table-wrap></sec><sec><title>Microsatellite analysis</title><p>Microsatellites located at 6p22 (see Figure <xref ref-type="fig" rid="F1">1</xref>) were amplified using published primer sets (see the ensembl database for sequences and T<sub>m</sub>s) in duplex reactions with one microsatellite from chromosome 12 (D12S1650) or chromosome 15 (D15S127) as control. These chromosome are rarely affected by allelic imbalances in bladder cancer [<xref ref-type="bibr" rid="B3">3</xref>]. One primer from each pair was labeled with IRD-800 fluorescence and the products were resolved and detected on a LiCOR 4200S automated sequencer. Reactions were carried out in the linear phase of PCR with 25&#x02013;30 cycles, the precise number being determined for each primer pair. Band intensities were quantitatively determined by ONE-D-SCAN (MWG-Biotech, Ebersberg, Germany). Leukocyte DNA standards were included in each set of reaction. The ratio of intensities of chromosome 6 and chromosome 15 microsatellites in these was set as 1 for each pair.</p></sec></sec><sec><title>Authors' contributions</title><p>QW performed most experiments and most of the data evaluation, aided and supported by MJH; FHH contributed and evaluated the clinical data; WAS conceived and supervised the study and drafted the manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>Excellent technical assistance by Ms. Andrea Prior is gratefully acknowledged.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knowles</surname><given-names>MA</given-names></name></person-group><article-title>What we could do now: molecular pathology of bladder cancer</article-title><source>Mol Pathol</source><year>2001</year><volume>54</volume><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">11477133</pub-id><pub-id pub-id-type="doi">10.1136/mp.54.4.215</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dinney</surname><given-names>CP</given-names></name><name><surname>McConkey</surname><given-names>DJ</given-names></name><name><surname>Millikan</surname><given-names>RE</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Bar-Eli</surname><given-names>M</given-names></name><name><surname>Adam</surname><given-names>L</given-names></name><name><surname>Kamat</surname><given-names>AM</given-names></name><name><surname>Siefker-Radtke</surname><given-names>AO</given-names></name><name><surname>Tuziak</surname><given-names>T</given-names></name><name><surname>Sabichi</surname><given-names>AL</given-names></name><name><surname>Grossman</surname><given-names>HB</given-names></name><name><surname>Benedict</surname><given-names>WF</given-names></name><name><surname>Czerniak</surname><given-names>B</given-names></name></person-group><article-title>Focus on bladder cancer</article-title><source>Cancer Cell</source><year>2004</year><volume>6</volume><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">15324694</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2004.08.002</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knowles</surname><given-names>MA</given-names></name><name><surname>Elder</surname><given-names>PA</given-names></name><name><surname>Williamson</surname><given-names>M</given-names></name><name><surname>Cairns</surname><given-names>JP</given-names></name><name><surname>Shaw</surname><given-names>ME</given-names></name><name><surname>Law</surname><given-names>MG</given-names></name></person-group><article-title>Allelotype of human bladder cancer</article-title><source>Cancer Res</source><year>1994</year><volume>54</volume><fpage>531</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">8275491</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hovey</surname><given-names>RM</given-names></name><name><surname>Chu</surname><given-names>L</given-names></name><name><surname>Balazs</surname><given-names>M</given-names></name><name><surname>DeVries</surname><given-names>S</given-names></name><name><surname>Moore</surname><given-names>D</given-names></name><name><surname>Sauter</surname><given-names>G</given-names></name><name><surname>Carroll</surname><given-names>PR</given-names></name><name><surname>Waldman</surname><given-names>FM</given-names></name></person-group><article-title>Genetic alterations in primary bladder cancers and their metastases</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>3555</fpage><lpage>3560</lpage><pub-id pub-id-type="pmid">9721860</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bruch</surname><given-names>J</given-names></name><name><surname>W&#x000f6;hr</surname><given-names>G</given-names></name><name><surname>Hautmann</surname><given-names>R</given-names></name><name><surname>Mattfeldt</surname><given-names>T</given-names></name><name><surname>Br&#x000fc;derlein</surname><given-names>S</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>P</given-names></name><name><surname>Sauter</surname><given-names>S</given-names></name><name><surname>Hameister</surname><given-names>H</given-names></name><name><surname>Vogel</surname><given-names>W</given-names></name><name><surname>Paiss</surname><given-names>T</given-names></name></person-group><article-title>Chromosomal changes during progression of transitional cell carcinoma of the bladder and delineation of the amplified interval on chromosome arm 8q</article-title><source>Genes Chromosomes Cancer</source><year>1998</year><volume>23</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">9739020</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1098-2264(199810)23:2&#x0003c;167::AID-GCC10&#x0003e;3.0.CO;2-L</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Veltman</surname><given-names>JA</given-names></name><name><surname>Fridlyand</surname><given-names>J</given-names></name><name><surname>Pejavar</surname><given-names>S</given-names></name><name><surname>Olshen</surname><given-names>AB</given-names></name><name><surname>Korkola</surname><given-names>JE</given-names></name><name><surname>DeVries</surname><given-names>S</given-names></name><name><surname>Carroll</surname><given-names>P</given-names></name><name><surname>Kuo</surname><given-names>WL</given-names></name><name><surname>Pinkel</surname><given-names>D</given-names></name><name><surname>Albertson</surname><given-names>D</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C</given-names></name><name><surname>Jain</surname><given-names>AN</given-names></name><name><surname>Waldman</surname><given-names>FM</given-names></name></person-group><article-title>Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>2872</fpage><lpage>2880</lpage><pub-id pub-id-type="pmid">12782593</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>CD</given-names></name><name><surname>Fiegler</surname><given-names>H</given-names></name><name><surname>Carr</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>S</given-names></name><name><surname>Carter</surname><given-names>NP</given-names></name><name><surname>Knowles</surname><given-names>MA</given-names></name></person-group><article-title>High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>2250</fpage><lpage>2263</lpage><pub-id pub-id-type="pmid">14968109</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1207260</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwab</surname><given-names>M</given-names></name></person-group><article-title>Oncogene amplification in solid tumors</article-title><source>Semin Cancer Biol</source><year>1999</year><volume>9</volume><fpage>319</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">10448118</pub-id><pub-id pub-id-type="doi">10.1006/scbi.1999.0126</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bruch</surname><given-names>J</given-names></name><name><surname>Schulz</surname><given-names>WA</given-names></name><name><surname>H&#x000e4;ussler</surname><given-names>J</given-names></name><name><surname>Melzner</surname><given-names>I</given-names></name><name><surname>Br&#x000fc;derlein</surname><given-names>S</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>P</given-names></name><name><surname>Kemmerling</surname><given-names>R</given-names></name><name><surname>Vogel</surname><given-names>W</given-names></name><name><surname>Hameister</surname><given-names>H</given-names></name></person-group><article-title>Delineation of the 6p22 amplification unit in urinary bladder carcinoma cell lines</article-title><source>Cancer Res</source><year>2000</year><volume>60</volume><fpage>4526</fpage><lpage>4530</lpage><pub-id pub-id-type="pmid">10969802</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>AJ</given-names></name><name><surname>Gallie</surname><given-names>BL</given-names></name><name><surname>Jewett</surname><given-names>MAS</given-names></name><name><surname>Pond</surname><given-names>GR</given-names></name><name><surname>Vandezande</surname><given-names>K</given-names></name><name><surname>Underwood</surname><given-names>J</given-names></name><name><surname>Fradet</surname><given-names>Y</given-names></name><name><surname>Lim</surname><given-names>G</given-names></name><name><surname>Marrano</surname><given-names>P</given-names></name><name><surname>Zielenska</surname><given-names>M</given-names></name><name><surname>Squire</surname><given-names>JA</given-names></name></person-group><article-title>Defining a 0.5-Mb region of genomic gain on chromosome 6p22 in bladder cancer by quantitative-multiplex polymerase chain reaction</article-title><source>Am J Pathol</source><year>2004</year><volume>164</volume><fpage>285</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">14695341</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feber</surname><given-names>A</given-names></name><name><surname>Clark</surname><given-names>J</given-names></name><name><surname>Goodwin</surname><given-names>G</given-names></name><name><surname>Dodson</surname><given-names>AR</given-names></name><name><surname>Smith</surname><given-names>PH</given-names></name><name><surname>Fletcher</surname><given-names>A</given-names></name><name><surname>Edwards</surname><given-names>S</given-names></name><name><surname>Flohr</surname><given-names>P</given-names></name><name><surname>Falconer</surname><given-names>A</given-names></name><name><surname>Roe</surname><given-names>T</given-names></name><name><surname>Kovacs</surname><given-names>G</given-names></name><name><surname>Dennis</surname><given-names>N</given-names></name><name><surname>Fisher</surname><given-names>C</given-names></name><name><surname>Wooster</surname><given-names>R</given-names></name><name><surname>Huddart</surname><given-names>R</given-names></name><name><surname>Foster</surname><given-names>CS</given-names></name><name><surname>Cooper</surname><given-names>CS</given-names></name></person-group><article-title>Amplification and overexpression of E2F3 in human bladder cancer</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>1627</fpage><lpage>1630</lpage><pub-id pub-id-type="pmid">14716298</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1207274</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oeggerli</surname><given-names>M</given-names></name><name><surname>Tomovska</surname><given-names>S</given-names></name><name><surname>Schraml</surname><given-names>P</given-names></name><name><surname>Calvano-Forte</surname><given-names>D</given-names></name><name><surname>Schafroth</surname><given-names>S</given-names></name><name><surname>Simon</surname><given-names>R</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Mihatsch</surname><given-names>MJ</given-names></name><name><surname>Sauter</surname><given-names>G</given-names></name></person-group><article-title>E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>5616</fpage><lpage>5623</lpage><pub-id pub-id-type="pmid">15122326</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1207749</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Carbayo</surname><given-names>M</given-names></name><name><surname>Socci</surname><given-names>ND</given-names></name><name><surname>Lozano</surname><given-names>JJ</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Charytonowicz</surname><given-names>E</given-names></name><name><surname>Belbin</surname><given-names>TJ</given-names></name><name><surname>Prystowsky</surname><given-names>MB</given-names></name><name><surname>Ortiz</surname><given-names>AR</given-names></name><name><surname>Childs</surname><given-names>G</given-names></name><name><surname>Cordon-Cardo</surname><given-names>C</given-names></name></person-group><article-title>Gene discovery in bladder cancer progression using cDNA microarrays</article-title><source>Am J Pathol</source><year>2003</year><volume>163</volume><fpage>505</fpage><lpage>516</lpage><pub-id pub-id-type="pmid">12875971</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mungall</surname><given-names>AJ</given-names></name><name><surname>Palmer</surname><given-names>SA</given-names></name><name><surname>Sims</surname><given-names>SK</given-names></name><name><surname>Edwards</surname><given-names>CA</given-names></name><name><surname>Ashurst</surname><given-names>JL</given-names></name><name><surname>Wilming</surname><given-names>L</given-names></name><name><surname>Jones</surname><given-names>MC</given-names></name><name><surname>Horton</surname><given-names>R</given-names></name><name><surname>Hunt</surname><given-names>SE</given-names></name><name><surname>Scott</surname><given-names>CE</given-names></name><name><surname>Gilbert</surname><given-names>JG</given-names></name><name><surname>Clamp</surname><given-names>ME</given-names></name><name><surname>Bethel</surname><given-names>G</given-names></name><name><surname>Milne</surname><given-names>S</given-names></name><name><surname>Ainscough</surname><given-names>R</given-names></name><name><surname>Almeida</surname><given-names>JP</given-names></name><name><surname>Ambrose</surname><given-names>KD</given-names></name><name><surname>Andrews</surname><given-names>TD</given-names></name><name><surname>Ashwell</surname><given-names>RI</given-names></name><name><surname>Babbage</surname><given-names>AK</given-names></name><name><surname>Bagguley</surname><given-names>CL</given-names></name><name><surname>Bailey</surname><given-names>J</given-names></name><name><surname>Banerjee</surname><given-names>R</given-names></name><name><surname>Barker</surname><given-names>DJ</given-names></name><name><surname>Barlow</surname><given-names>KF</given-names></name><name><surname>Bates</surname><given-names>K</given-names></name><name><surname>Beare</surname><given-names>DM</given-names></name><name><surname>Beasley</surname><given-names>H</given-names></name><name><surname>Beasley</surname><given-names>O</given-names></name><name><surname>Bird</surname><given-names>CP</given-names></name><name><surname>Blakey</surname><given-names>S</given-names></name><name><surname>Bray-Allen</surname><given-names>S</given-names></name><name><surname>Brook</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>AJ</given-names></name><name><surname>Brown</surname><given-names>JY</given-names></name><name><surname>Burford</surname><given-names>DC</given-names></name><name><surname>Burrill</surname><given-names>W</given-names></name><name><surname>Burton</surname><given-names>J</given-names></name><name><surname>Carder</surname><given-names>C</given-names></name><name><surname>Carter</surname><given-names>NP</given-names></name><name><surname>Chapman</surname><given-names>JC</given-names></name><name><surname>Clark</surname><given-names>SY</given-names></name><name><surname>Clark</surname><given-names>G</given-names></name><name><surname>Clee</surname><given-names>CM</given-names></name><name><surname>Clegg</surname><given-names>S</given-names></name><name><surname>Cobley</surname><given-names>V</given-names></name><name><surname>Collier</surname><given-names>RE</given-names></name><name><surname>Collins</surname><given-names>JE</given-names></name><name><surname>Colman</surname><given-names>LK</given-names></name><name><surname>Corby</surname><given-names>NR</given-names></name><name><surname>Coville</surname><given-names>GJ</given-names></name><name><surname>Culley</surname><given-names>KM</given-names></name><name><surname>Dhami</surname><given-names>P</given-names></name><name><surname>Davies</surname><given-names>J</given-names></name><name><surname>Dunn</surname><given-names>M</given-names></name><name><surname>Earthrowl</surname><given-names>ME</given-names></name><name><surname>Ellington</surname><given-names>AE</given-names></name><name><surname>Evans</surname><given-names>KA</given-names></name><name><surname>Faulkner</surname><given-names>L</given-names></name><name><surname>Francis</surname><given-names>MD</given-names></name><name><surname>Frankish</surname><given-names>A</given-names></name><name><surname>Frankland</surname><given-names>J</given-names></name><name><surname>French</surname><given-names>L</given-names></name><name><surname>Garner</surname><given-names>P</given-names></name><name><surname>Garnett</surname><given-names>J</given-names></name><name><surname>Ghori</surname><given-names>MJ</given-names></name><name><surname>Gilby</surname><given-names>LM</given-names></name><name><surname>Gillson</surname><given-names>CJ</given-names></name><name><surname>Glithero</surname><given-names>RJ</given-names></name><name><surname>Grafham</surname><given-names>DV</given-names></name><name><surname>Grant</surname><given-names>M</given-names></name><name><surname>Gribble</surname><given-names>S</given-names></name><name><surname>Griffiths</surname><given-names>C</given-names></name><name><surname>Griffiths</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>R</given-names></name><name><surname>Halls</surname><given-names>KS</given-names></name><name><surname>Hammond</surname><given-names>S</given-names></name><name><surname>Harley</surname><given-names>JL</given-names></name><name><surname>Hart</surname><given-names>EA</given-names></name><name><surname>Heath</surname><given-names>PD</given-names></name><name><surname>Heathcott</surname><given-names>R</given-names></name><name><surname>Holmes</surname><given-names>SJ</given-names></name><name><surname>Howden</surname><given-names>PJ</given-names></name><name><surname>Howe</surname><given-names>KL</given-names></name><name><surname>Howell</surname><given-names>GR</given-names></name><name><surname>Huckle</surname><given-names>E</given-names></name><name><surname>Humphray</surname><given-names>SJ</given-names></name><name><surname>Humphries</surname><given-names>MD</given-names></name><name><surname>Hunt</surname><given-names>AR</given-names></name><name><surname>Johnson</surname><given-names>CM</given-names></name><name><surname>Joy</surname><given-names>AA</given-names></name><name><surname>Kay</surname><given-names>M</given-names></name><name><surname>Keenan</surname><given-names>SJ</given-names></name><name><surname>Kimberley</surname><given-names>AM</given-names></name><name><surname>King</surname><given-names>A</given-names></name><name><surname>Laird</surname><given-names>GK</given-names></name><name><surname>Langford</surname><given-names>C</given-names></name><name><surname>Lawlor</surname><given-names>S</given-names></name><name><surname>Leongamornlert</surname><given-names>DA</given-names></name><name><surname>Leversha</surname><given-names>M</given-names></name><name><surname>Lloyd</surname><given-names>CR</given-names></name><name><surname>Lloyd</surname><given-names>DM</given-names></name><name><surname>Loveland</surname><given-names>JE</given-names></name><name><surname>Lovell</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Mashreghi-Mohammadi</surname><given-names>M</given-names></name><name><surname>Maslen</surname><given-names>GL</given-names></name><name><surname>Matthews</surname><given-names>L</given-names></name><name><surname>McCann</surname><given-names>OT</given-names></name><name><surname>McLaren</surname><given-names>SJ</given-names></name><name><surname>McLay</surname><given-names>K</given-names></name><name><surname>McMurray</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Mullikin</surname><given-names>JC</given-names></name><name><surname>Niblett</surname><given-names>D</given-names></name><name><surname>Nickerson</surname><given-names>T</given-names></name><name><surname>Novik</surname><given-names>KL</given-names></name><name><surname>Oliver</surname><given-names>K</given-names></name><name><surname>Overton-Larty</surname><given-names>EK</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Pearce</surname><given-names>AV</given-names></name><name><surname>Peck</surname><given-names>AI</given-names></name><name><surname>Phillimore</surname><given-names>B</given-names></name><name><surname>Phillips</surname><given-names>S</given-names></name><name><surname>Plumb</surname><given-names>RW</given-names></name><name><surname>Porter</surname><given-names>KM</given-names></name><name><surname>Ramsey</surname><given-names>Y</given-names></name><name><surname>Ranby</surname><given-names>SA</given-names></name><name><surname>Rice</surname><given-names>CM</given-names></name><name><surname>Ross</surname><given-names>MT</given-names></name><name><surname>Searle</surname><given-names>SM</given-names></name><name><surname>Sehra</surname><given-names>HK</given-names></name><name><surname>Sheridan</surname><given-names>E</given-names></name><name><surname>Skuce</surname><given-names>CD</given-names></name><name><surname>Smith</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><name><surname>Spraggon</surname><given-names>L</given-names></name><name><surname>Squares</surname><given-names>SL</given-names></name><name><surname>Steward</surname><given-names>CA</given-names></name><name><surname>Sycamore</surname><given-names>N</given-names></name><name><surname>Tamlyn-Hall</surname><given-names>G</given-names></name><name><surname>Tester</surname><given-names>J</given-names></name><name><surname>Theaker</surname><given-names>AJ</given-names></name><name><surname>Thomas</surname><given-names>DW</given-names></name><name><surname>Thorpe</surname><given-names>A</given-names></name><name><surname>Tracey</surname><given-names>A</given-names></name><name><surname>Tromans</surname><given-names>A</given-names></name><name><surname>Tubby</surname><given-names>B</given-names></name><name><surname>Wall</surname><given-names>M</given-names></name><name><surname>Wallis</surname><given-names>JM</given-names></name><name><surname>West</surname><given-names>AP</given-names></name><name><surname>White</surname><given-names>SS</given-names></name><name><surname>Whitehead</surname><given-names>SL</given-names></name><name><surname>Whittaker</surname><given-names>H</given-names></name><name><surname>Wild</surname><given-names>A</given-names></name><name><surname>Willey</surname><given-names>DJ</given-names></name><name><surname>Wilmer</surname><given-names>TE</given-names></name><name><surname>Wood</surname><given-names>JM</given-names></name><name><surname>Wray</surname><given-names>PW</given-names></name><name><surname>Wyatt</surname><given-names>JC</given-names></name><name><surname>Young</surname><given-names>L</given-names></name><name><surname>Younger</surname><given-names>RM</given-names></name><name><surname>Bentley</surname><given-names>DR</given-names></name><name><surname>Coulson</surname><given-names>A</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name><name><surname>Hubbard</surname><given-names>T</given-names></name><name><surname>Sulston</surname><given-names>JE</given-names></name><name><surname>Dunham</surname><given-names>I</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Beck</surname><given-names>S</given-names></name></person-group><article-title>The DNA sequence and analysis of human chromosome 6</article-title><source>Nature</source><year>2003</year><volume>425</volume><fpage>805</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">14574404</pub-id><pub-id pub-id-type="doi">10.1038/nature02055</pub-id></citation></ref><ref id="B15"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Israel</surname><given-names>MA</given-names></name><name><surname>Hernandez</surname><given-names>MC</given-names></name><name><surname>Florio</surname><given-names>M</given-names></name><name><surname>Andres-Barquin</surname><given-names>PJ</given-names></name><name><surname>Mantani</surname><given-names>A</given-names></name><name><surname>Carter</surname><given-names>JH</given-names></name><name><surname>Julin</surname><given-names>CM</given-names></name></person-group><article-title>Id gene expression as a key mediator of tumor cell biology</article-title><source>Cancer Res</source><year>1999</year><fpage>1726s</fpage><lpage>1730s</lpage><pub-id pub-id-type="pmid">10197587</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Norton</surname><given-names>JD</given-names></name></person-group><article-title>ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis</article-title><source>J Cell Sci</source><year>2000</year><volume>113</volume><fpage>3897</fpage><lpage>3905</lpage><pub-id pub-id-type="pmid">11058077</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lasorella</surname><given-names>A</given-names></name><name><surname>Uo</surname><given-names>T</given-names></name><name><surname>Iavarone</surname><given-names>A</given-names></name></person-group><article-title>Id proteins at the cross-road of development and cancer</article-title><source>Oncogene</source><year>2001</year><volume>20</volume><fpage>8326</fpage><lpage>8333</lpage><pub-id pub-id-type="pmid">11840325</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1205093</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sikder</surname><given-names>HA</given-names></name><name><surname>Devlin</surname><given-names>MK</given-names></name><name><surname>Dunlap</surname><given-names>S</given-names></name><name><surname>Ryu</surname><given-names>B</given-names></name><name><surname>Alani</surname><given-names>RM</given-names></name></person-group><article-title>Id proteins in cell growth and tumorigenesis</article-title><source>Cancer Cell</source><year>2003</year><volume>3</volume><fpage>525</fpage><pub-id pub-id-type="pmid">12842081</pub-id><pub-id pub-id-type="doi">10.1016/S1535-6108(03)00141-7</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riechmann</surname><given-names>V</given-names></name><name><surname>van Cr&#x000fc;chten</surname><given-names>I</given-names></name><name><surname>Sablitzky</surname><given-names>F</given-names></name></person-group><article-title>The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3</article-title><source>Nucleic Acids Res</source><year>1994</year><volume>22</volume><fpage>749</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">8139914</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mysorekar</surname><given-names>IU</given-names></name><name><surname>Mulvey</surname><given-names>MA</given-names></name><name><surname>Hultgren</surname><given-names>SJ</given-names></name><name><surname>Gordon</surname><given-names>JI</given-names></name></person-group><article-title>Molecular regulation of urothelial renewal and host defenses during infection with uropathogenic Escherichia coli</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>7412</fpage><lpage>7419</lpage><pub-id pub-id-type="pmid">11744708</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M110560200</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Southgate</surname><given-names>J</given-names></name><name><surname>Hutton</surname><given-names>KA</given-names></name><name><surname>Thomas</surname><given-names>DF</given-names></name><name><surname>Trejdosiewicz</surname><given-names>LK</given-names></name></person-group><article-title>Normal human urothelial cells in vitro: proliferation and induction of stratification</article-title><source>Lab Invest</source><year>1994</year><volume>71</volume><fpage>583</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">7967513</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>MR</given-names></name><name><surname>Yoo</surname><given-names>JJ</given-names></name><name><surname>Raab</surname><given-names>G</given-names></name><name><surname>Soker</surname><given-names>S</given-names></name><name><surname>Adam</surname><given-names>RM</given-names></name><name><surname>Schneck</surname><given-names>FX</given-names></name><name><surname>Renshaw</surname><given-names>AA</given-names></name><name><surname>Klagsbrun</surname><given-names>M</given-names></name><name><surname>Atala</surname><given-names>A</given-names></name></person-group><article-title>Heparin-binding EGF-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized by epithelial and smooth muscle cells in the human bladder</article-title><source>J Clin Invest</source><year>1997</year><volume>99</volume><fpage>1028</fpage><lpage>1036</lpage><pub-id pub-id-type="pmid">9062361</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Swiatkowski</surname><given-names>S</given-names></name><name><surname>Seifert</surname><given-names>HH</given-names></name><name><surname>Steinhoff</surname><given-names>C</given-names></name><name><surname>Prior</surname><given-names>A</given-names></name><name><surname>Thievessen</surname><given-names>I</given-names></name><name><surname>Schliess</surname><given-names>F</given-names></name><name><surname>Schulz</surname><given-names>WA</given-names></name></person-group><article-title>Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines</article-title><source>Exp Cell Res</source><year>2003</year><volume>282</volume><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">12490193</pub-id><pub-id pub-id-type="doi">10.1006/excr.2002.5647</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Simon</surname><given-names>R</given-names></name><name><surname>Atefy</surname><given-names>R</given-names></name><name><surname>Wagner</surname><given-names>U</given-names></name><name><surname>Forster</surname><given-names>T</given-names></name><name><surname>Fijan</surname><given-names>A</given-names></name><name><surname>Bruderer</surname><given-names>J</given-names></name><name><surname>Wilber</surname><given-names>K</given-names></name><name><surname>Mihatsch</surname><given-names>MJ</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Sauter</surname><given-names>G</given-names></name></person-group><article-title>HER-2 and TOP2A coamplification in urinary bladder cancer</article-title><source>Int J Cancer</source><year>2003</year><volume>107</volume><fpage>764</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">14566826</pub-id><pub-id pub-id-type="doi">10.1002/ijc.11477</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuwahara</surname><given-names>Y</given-names></name><name><surname>Tanabe</surname><given-names>C</given-names></name><name><surname>Ikeuchi</surname><given-names>T</given-names></name><name><surname>Aoyagi</surname><given-names>K</given-names></name><name><surname>Nishigaki</surname><given-names>M</given-names></name><name><surname>Sakamoto</surname><given-names>H</given-names></name><name><surname>Hoshinaga</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Terada</surname><given-names>M</given-names></name></person-group><article-title>Alternative mechanisms of gene amplification in human cancers</article-title><source>Genes Chromosomes Cancer</source><year>2004</year><volume>41</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">15287025</pub-id><pub-id pub-id-type="doi">10.1002/gcc.20075</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vogt</surname><given-names>N</given-names></name><name><surname>Lefebre</surname><given-names>SH</given-names></name><name><surname>Apiou</surname><given-names>F</given-names></name><name><surname>Dutrillaux</surname><given-names>AM</given-names></name><name><surname>Cor</surname><given-names>A</given-names></name><name><surname>Leuraud</surname><given-names>P</given-names></name><name><surname>Poupon</surname><given-names>MF</given-names></name><name><surname>Dutrillaux</surname><given-names>B</given-names></name><name><surname>Debatisse</surname><given-names>M</given-names></name><name><surname>Malfoy</surname><given-names>B</given-names></name></person-group><article-title>Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas</article-title><source>Proc Natl Acad Sci USA</source><year>2004</year><volume>101</volume><fpage>11368</fpage><lpage>11373</lpage><pub-id pub-id-type="pmid">15269346</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0402979101</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>JW</given-names></name><name><surname>Imoto</surname><given-names>I</given-names></name><name><surname>Inoue</surname><given-names>J</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><name><surname>Ueda</surname><given-names>M</given-names></name><name><surname>Imamura</surname><given-names>M</given-names></name><name><surname>Bartram</surname><given-names>CR</given-names></name><name><surname>Inazawa</surname><given-names>J</given-names></name></person-group><article-title>MYEOV, a gene at 11q13, is coamplified with CCND1, but epigenetically inactivated in a subset of esophageal squamous cell carcinomas</article-title><source>J Hum Genet</source><year>2002</year><volume>47</volume><fpage>460</fpage><lpage>464</lpage><pub-id pub-id-type="pmid">12202983</pub-id><pub-id pub-id-type="doi">10.1007/s100380200065</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Volik</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Chin</surname><given-names>K</given-names></name><name><surname>Brebner</surname><given-names>JH</given-names></name><name><surname>Herndon</surname><given-names>DR</given-names></name><name><surname>Tao</surname><given-names>Q</given-names></name><name><surname>Kowbel</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Lapuk</surname><given-names>A</given-names></name><name><surname>Kuo</surname><given-names>WL</given-names></name><name><surname>Magrane</surname><given-names>G</given-names></name><name><surname>De Jong</surname><given-names>P</given-names></name><name><surname>Gray</surname><given-names>JW</given-names></name><name><surname>Collins</surname><given-names>C</given-names></name></person-group><article-title>End-sequence profiling: sequence-based analysis of aberrant genomes</article-title><source>Proc Natl Acad Sci USA</source><year>2003</year><volume>100</volume><fpage>7696</fpage><lpage>7701</lpage><pub-id pub-id-type="pmid">12788976</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1232418100</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>ZQ</given-names></name><name><surname>Albertson</surname><given-names>D</given-names></name><name><surname>Ethier</surname><given-names>SP</given-names></name></person-group><article-title>Genomic organization of the 8p11-p12 amplicon in three breast cancer cell lines</article-title><source>Cancer Genet Cytogenet</source><year>2004</year><volume>155</volume><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15527903</pub-id><pub-id pub-id-type="doi">10.1016/j.cancergencyto.2004.03.013</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zatkova</surname><given-names>A</given-names></name><name><surname>Ullmann</surname><given-names>R</given-names></name><name><surname>Rouillard</surname><given-names>JM</given-names></name><name><surname>Lamb</surname><given-names>BJ</given-names></name><name><surname>Kuick</surname><given-names>R</given-names></name><name><surname>Hanash</surname><given-names>SM</given-names></name><name><surname>Schnittger</surname><given-names>S</given-names></name><name><surname>Schoch</surname><given-names>C</given-names></name><name><surname>Fonatsch</surname><given-names>C</given-names></name><name><surname>Wimmer</surname><given-names>K</given-names></name></person-group><article-title>Distinct sequences on 11q13.5 and 11q23-24 are frequently coamplified with MLL in complexly organized 11q amplicons in AML/MDS patients</article-title><source>Genes Chromosomes Cancer</source><year>2004</year><volume>39</volume><fpage>263</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">14978788</pub-id><pub-id pub-id-type="doi">10.1002/gcc.20002</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coquelle</surname><given-names>A</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name><name><surname>Stern</surname><given-names>S</given-names></name><name><surname>Bieth</surname><given-names>A</given-names></name><name><surname>Debatisse</surname><given-names>M</given-names></name></person-group><article-title>A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs</article-title><source>Mol Cell</source><year>1998</year><volume>2</volume><fpage>259</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">9734364</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(00)80137-9</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hellman</surname><given-names>A</given-names></name><name><surname>Zlotorynski</surname><given-names>E</given-names></name><name><surname>Scherer</surname><given-names>SW</given-names></name><name><surname>Cheung</surname><given-names>J</given-names></name><name><surname>Vincent</surname><given-names>JB</given-names></name><name><surname>Smith</surname><given-names>DI</given-names></name><name><surname>Trakhtenbrot</surname><given-names>L</given-names></name><name><surname>Kerem</surname><given-names>B</given-names></name></person-group><article-title>A role for common fragile site induction in amplification of human oncogenes</article-title><source>Cancer Cell</source><year>2002</year><volume>1</volume><fpage>89</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">12086891</pub-id><pub-id pub-id-type="doi">10.1016/S1535-6108(02)00017-X</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Wilhelm</surname><given-names>D</given-names></name><name><surname>Koopman</surname><given-names>P</given-names></name></person-group><article-title>Sox genes and cancer</article-title><source>Cytogenet Genome Res</source><year>2004</year><volume>105</volume><fpage>442</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">15237232</pub-id><pub-id pub-id-type="doi">10.1159/000078217</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aslanian</surname><given-names>A</given-names></name><name><surname>Iaquinta</surname><given-names>PJ</given-names></name><name><surname>Verona</surname><given-names>R</given-names></name><name><surname>Lees</surname><given-names>JA</given-names></name></person-group><article-title>Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics</article-title><source>Genes Dev</source><year>2004</year><volume>18</volume><fpage>1413</fpage><lpage>1422</lpage><pub-id pub-id-type="pmid">15175242</pub-id><pub-id pub-id-type="doi">10.1101/gad.1196704</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>von Lindern</surname><given-names>M</given-names></name><name><surname>Fornerod</surname><given-names>M</given-names></name><name><surname>van Baal</surname><given-names>S</given-names></name><name><surname>Jaegle</surname><given-names>M</given-names></name><name><surname>de Wit</surname><given-names>T</given-names></name><name><surname>Buijs</surname><given-names>A</given-names></name><name><surname>Grosveld</surname><given-names>G</given-names></name></person-group><article-title>The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA</article-title><source>Mol Cell Biol</source><year>1992</year><volume>12</volume><fpage>1687</fpage><lpage>1697</lpage><pub-id pub-id-type="pmid">1549122</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Qiu</surname><given-names>C</given-names></name><name><surname>Snyderwine</surname><given-names>EG</given-names></name></person-group><article-title>Id4 regulates mammary epithelial cell growth and differentiation and is overexpressed in rat mammary gland carcinomas</article-title><source>Am J Pathol</source><year>2003</year><volume>163</volume><fpage>2495</fpage><lpage>2502</lpage><pub-id pub-id-type="pmid">14633621</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bellido</surname><given-names>M</given-names></name><name><surname>Aventin</surname><given-names>A</given-names></name><name><surname>Lasa</surname><given-names>A</given-names></name><name><surname>Estivill</surname><given-names>C</given-names></name><name><surname>Carnicer</surname><given-names>MJ</given-names></name><name><surname>Pons</surname><given-names>C</given-names></name><name><surname>Matias-Guiu</surname><given-names/></name><name><surname>Bordes</surname><given-names>R</given-names></name><name><surname>Baiget</surname><given-names>M</given-names></name><name><surname>Sierra</surname><given-names>J</given-names></name><name><surname>Nomded&#x000e9;u</surname><given-names>JF</given-names></name></person-group><article-title>Id4 is deregulated by a t(6;14)(p22;q32) chromosomal translocation in a B-cell lineage acute lymphoblastic leukemia</article-title><source>J Hematol</source><year>2003</year><volume>88</volume><fpage>994</fpage><lpage>1001</lpage></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Umetani</surname><given-names>N</given-names></name><name><surname>Takeuchi</surname><given-names>H</given-names></name><name><surname>Fujimoto</surname><given-names>A</given-names></name><name><surname>Shinozaki</surname><given-names>M</given-names></name><name><surname>Bilchik</surname><given-names>AJ</given-names></name><name><surname>Hoon</surname><given-names>DS</given-names></name></person-group><article-title>Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis</article-title><source>Clin Cancer Res</source><year>2004</year><volume>10</volume><fpage>7475</fpage><lpage>7483</lpage><pub-id pub-id-type="pmid">15569977</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Florl</surname><given-names>AR</given-names></name><name><surname>Franke</surname><given-names>KH</given-names></name><name><surname>Niederacher</surname><given-names>D</given-names></name><name><surname>Gerharz</surname><given-names>CD</given-names></name><name><surname>Seifert</surname><given-names>HH</given-names></name><name><surname>Schulz</surname><given-names>WA</given-names></name></person-group><article-title>DNA methylation and the mechanisms of <italic>CDKN2A </italic>inactivation in transitional cell carcinoma of the urinary bladder</article-title><source>Lab Invest</source><year>2000</year><volume>80</volume><fpage>1513</fpage><lpage>1522</lpage><pub-id pub-id-type="pmid">11045568</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>BA</given-names></name><name><surname>Rose</surname><given-names>A</given-names></name><name><surname>Steinhoff</surname><given-names>C</given-names></name><name><surname>Strohmeyer</surname><given-names>T</given-names></name><name><surname>Hartmann</surname><given-names>M</given-names></name><name><surname>Ackermann</surname><given-names>R</given-names></name></person-group><article-title>Up-regulation of cyclin-dependent kinase 4/cyclin D2 expression but down-regulation of cyclin-dependent kinase 2/cyclin E in testicular germ cell tumors</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>4214</fpage><lpage>4221</lpage><pub-id pub-id-type="pmid">11358847</pub-id></citation></ref></ref-list></back></article> 